American Society of Regional Anesthesia and Pain Medicine guidelines highlight SSI prevention in regional anesthesia and ...
A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback